Fortrea Holdings Inc. - Common Stock (FTRE)

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind...

Fortrea’s first quarter results were well received by investors, as the company exceeded Wall Street expectations on both revenue and non-GAAP earnings. Mana...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) reported Q1 CY2026 results topping the market’s revenue expectations, but sales fell by 2.3% year on...

What Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 20.3% in the morning session after it reported first-quarter 2026 re...

Fortrea (FTRE) Q1 2026 Earnings Transcript

Clinical research company Fortrea Holdings (NASDAQ:FTRE) announced better-than-expected revenue in Q1 CY2026, but sales fell by 2.3% year on year to $636.5 m...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings this Tuesday before market open. Here’s what to look for. Fortrea missed ...

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Fortrea has been treading water for the past six months, recording a small loss of 1.7% while holding steady at $9.39. Is there a buying opportunity in Fortr...

What Happened? A number of stocks jumped in the afternoon session after the government announced a surprise increase in payment rates for Medicare Advantage ...

What Happened? A number of stocks fell in the afternoon session after a proposed 2027 federal budget revealed significant spending cuts for key health agenci...

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have not only realized strong financial ...

What Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 2.8% in the afternoon session after TD Cowen upgraded the company to...

What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Fortrea (NASDAQ:FTRE) and its peers.

Fortrea (FTRE) Q4 2025 Earnings Call Transcript